This site is intended for health professionals only

At the heart of general practice since 1960

Read the latest issue online

Gold, incentives and meh

Report this comment to a moderator

Please fill in the form below if you think a comment is unsuitable. Your comments will be sent to our moderator for review.

Report comment to moderator

Required fields.

Headline

NICE recommends 'game-changing' heart failure drug

Comment

PARADIGM-HF trial: Sacubitril (blocks the enzyme ,neprilysn , which in turn,breaks down BNP and ANP). Together with valsartan(LCZ696)versus enalapril: The trial was stopped early, according to prespecified rules, after a median follow-up of 27 months, because the boundary for an overwhelming benefit with LCZ696 had been crossed. At the time of study closure, the primary outcome had occurred in 914 patients (21.8%) in the LCZ696 group and 1117 patients (26.5%) in the enalapril group (hazard ratio in the LCZ696 group, 0.80; 95% confidence interval [CI], 0.73 to 0.87; P

Posted date

27 Apr 2016

Posted time

1:07pm

required
required
required